Updated:
Senju Pharmaceutical Co.
Senju Pharmaceutical Co. is a Japanese family office focused on ophthalmic R&D, known for launching Abarept in 2026.
Senju Pharmaceutical Co.
Senju Pharmaceutical Co. was founded in Osaka, Japan, and remains privately held. The firm's core business is the research, development, and commercialization of ophthalmic pharmaceuticals, with a particular emphasis on dry eye and glaucoma therapies. The firm's 2026 launch of Abarept, a first-in-class TRPV1 antagonist for dry eye, illustrates its focus on ophthalmic innovation through R&D and commercial partnerships. The company operates through a dedicated research institute and a biosimilar council, and has a subsidiary in Westmount, Canada. The firm's scale is undisclosed, but it maintains a major headquarters building in Osaka and a Canadian office. In March 2026, Senju participated in World Glaucoma Week, supporting awareness campaigns. Senju's structural differentiator is its integration of pharmaceutical manufacturing with a family office mandate, allowing it to reinvest profits directly into ophthalmic R&D without external shareholder pressure.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
Japan
City
Osaka
Corporate office
Osaka, Japan
Sector focus
Frequently asked questions
Who runs investment decisions at Senju Pharmaceutical Co.?
The firm's investment decisions are made by the founding family and executive team. Leadership details are not publicly disclosed.
How does Senju source proprietary deal flow?
Senju sources internal R&D through its own research institute and partners with external organizations via the Biosimilar Council and other alliances. The firm does not publicly detail deal sourcing.
Is Senju structured as a single family office or does it operate more like a pharmaceutical company?
Senju operates as a privately held pharmaceutical company that functions as a single family office. It reinvests profits from commercial drugs into further R&D without external funding.
What investment stages does Senju typically target?
Senju focuses on early-stage and late-stage ophthalmic drug development. Evidence includes the 2026 Abarept launch, a first-in-class treatment for dry eye.
Which sectors does Senju explicitly avoid?
The firm does not disclose sectors it avoids. Its public activity centers almost entirely on ophthalmology and pharmaceuticals.
How is Senju related to its international subsidiaries?
Senju owns a subsidiary in Westmount, Canada, which supports its global ophthalmic business. The company's Japanese headquarters remains the primary operational base.
Where does the underlying wealth come from?
The firm's wealth originates from the founding family's ownership of Senju Pharmaceutical, a profitable Japanese drugmaker focused on ophthalmic products. No further details are publicly available.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: